T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies targe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoseini, Sayed Shahabuddin, Vadlamudi, Mallika, Espinosa-Cotton, Madelyn, Tran, Hoa, Feng, Yi, Guo, Hong-fen, Xu, Hong, Cheung, Irene, Cheung, Nai-Kong V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154967/
https://www.ncbi.nlm.nih.gov/pubmed/34035113
http://dx.doi.org/10.1136/jitc-2021-002509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154967/
https://www.ncbi.nlm.nih.gov/pubmed/34035113
http://dx.doi.org/10.1136/jitc-2021-002509

Ejemplares similares